Last reviewed · How we verify
LMN-101
At a glance
| Generic name | LMN-101 |
|---|---|
| Also known as | Variable heavy chain (VHH) binding protein against flagellin |
| Sponsor | Lumen Bioscience, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- LMN-101 in a Campylobacter Human Challenge Model (PHASE2)
- Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMN-101 CI brief — competitive landscape report
- LMN-101 updates RSS · CI watch RSS
- Lumen Bioscience, Inc. portfolio CI